Compared, cited
Semaglutide vs Retatrutide
Semaglutide activates one gut-hormone receptor and is FDA-approved. Retatrutide activates three and is still in trials. The gap in the trial numbers is large - and so is the gap in how established each one is.
Last updated August 2026
Pepteca is a cited peptide reference. We do not sell peptides and take no affiliate money. Every figure below traces to a source on the linked library pages, with a clear line between what is clinically studied and what is community-reported.
| At a glance | Semaglutide | Retatrutide |
|---|---|---|
| Receptors | GLP-1 only | GLP-1 + GIP + glucagon (triple) |
| Status | FDA-approved | Investigational; Phase 3 ongoing |
| Best trial weight loss | -14.9% average (STEP 1, Wegovy, 68 wk) | -24.2% average (Phase 2, 12 mg, 48 wk) |
| Half-life | ~7 days | ~6 days |
| Availability | Prescribable | Not available; clinical trials only |
One receptor versus three
Semaglutide mimics GLP-1 alone. Retatrutide targets three receptors - GLP-1, GIP, and glucagon. The added glucagon activity may increase energy expenditure, the leading explanation for the larger average weight loss in retatrutide's Phase 2 trial.
Approved versus investigational
Semaglutide is FDA-approved, widely prescribed, and has years of real-world use. Retatrutide is investigational, in ongoing Phase 3 trials, with no approved dose and a safety profile still being established. Anything sold as retatrutide outside a trial is unapproved.
Reading the numbers carefully
Retatrutide's -24.2% is Phase 2 (338 people, 48 weeks); semaglutide's -14.9% is the STEP 1 Phase 3 result for Wegovy. These are separate trials, not a head-to-head, and both figures are averages with wide individual variation.
Who fits which
Semaglutide
Available now, FDA-approved, with an established track record and an oral option for diabetes.
Retatrutide
Only in trials. Strong Phase 2 signal, but not proven long-term and not a legal approved medication.
The cited card
Semaglutide
GLP-1 agonist
The cited card
Retatrutide
GLP-1 / GIP / glucagon triple agonist
Questions people ask
Is retatrutide stronger than semaglutide?
In separate trials, retatrutide produced a larger average weight loss (about 24%) than semaglutide (about 15% for Wegovy in STEP 1). But these were not compared head-to-head, retatrutide is investigational, and it is not FDA-approved. Educational information, not medical advice.
Where can I get retatrutide?
Only through a clinical trial. It has no FDA approval and is not legally available as a prescribed drug.
Sources
- [1]Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1), NEJM 2021Semaglutide 2.4 mg (Wegovy): -14.9% mean weight change at 68 weeks.
- [2]Triple-Hormone-Receptor Agonist Retatrutide for Obesity, Phase 2, NEJM 2023Retatrutide 12 mg: -24.2% mean weight loss at 48 weeks vs -2.1% placebo.
Full cited data for each compound is on its library page, linked above. Weight-loss figures are trial averages; individual results vary.
Related comparisons